Porphyria Treatment |
Panhematin Treatment for Hepatic Porphyria (AIP, VP, HCP)
Treatment for Canadians with Acute Hepatic Porphyria
Panhematin is distributed by Canadian Blood Services. Please see the following for more information:
CBS_Launch_letter-June_2019_EN.pdf
CL 2019-21 Launch of Panhematin (Hemin for injection)2019-08-28_.pdf
CL 2019-21 Launch of Panhematin (Hemin for injection)2019-08-28__FR (003).pdf
panhematin-product-monograph-ENG.pdf
Sample_Request_for_Patient_Designated_Plasma_Protein_Products_0.pdf
Treatment Guidelines for Canadians with Acute Hepatic Porphyria
There are no specific Canadian Treatment Guidelines for Canadians with Acute Hepatic Porphyria. The following best practice guideline and recommendations are included below. The Porphyrias Consortium in the United States has Treatment and Prognosis for the Acute Porphyrias information for Panhematin.
Recommendations for the Diagnosis and Treatment of the Acute Porphyria
Source: Product Information - Orphan Europe
Last Updated: 12/January/2017
Medical Disclaimer
Care has been taken to ensure that the information on this website is accurate at the time of publication. This information is, however, intended for general guidance only and is not meant to substitute consultation from a recognized health professional. The Canadian Association for Porphyria/Association Canadienne de Porphyrie disclaims for itself and for the author of this information, all responsibility for any mis-statements or for consequences of actions taken by any person while acting on information contained herein. Physicians and patients must make their own decisions about therapy according to the individual circumstances of each case.